首页 > 最新文献

Translational gastroenterology and hepatology最新文献

英文 中文
Impact of immune tolerance mechanisms on the efficacy of immunotherapy in primary and secondary liver cancers. 免疫耐受机制对原发性和继发性肝癌免疫治疗疗效的影响。
IF 3 4区 医学 Q1 Medicine Pub Date : 2023-01-01 DOI: 10.21037/tgh-23-11
Kamya Sankar, Ashley N Pearson, Tejaswi Worlikar, Matthew D Perricone, Erin A Holcomb, Mishal Mendiratta-Lala, Zhen Xu, Neil Bhowmick, Michael D Green

The liver is a functionally unique organ with an immunosuppressive microenvironment. The liver is the sixth most common site of primary cancer in humans and is a frequent site of metastasis from other solid tumors. The development of effective therapies for primary and metastatic liver cancer has been challenging due to the complex metabolic and immune microenvironment of the liver. The liver tumor microenvironment (TME) in primary and secondary (metastatic) liver cancers is heterogenous and consists of unique immune and stromal cell populations. Crosstalk between these cell populations and tumor cells creates an immunosuppressive microenvironment within the liver which potentiates cancer progression. Immune checkpoint inhibitors (ICIs) are now clinically approved for the management of primary and secondary liver cancer and can partially overcome liver immune tolerance, but their efficacy is limited. In this review, we describe the liver microenvironment and the use of immunotherapy in primary and secondary liver cancer. We discuss emerging combination strategies utilizing locoregional and systemic therapy approaches which may enhance efficacy of immunotherapy in primary and secondary liver cancer. A deeper understanding of the immunosuppressive microenvironment of the liver will inform novel therapies and therapeutic combinations in order to improve outcomes of patients with primary and secondary liver cancer.

肝脏是一个功能独特的器官,具有免疫抑制微环境。肝脏是人类原发癌症的第六大常见部位,也是其他实体肿瘤转移的常见部位。由于肝脏复杂的代谢和免疫微环境,开发有效的治疗原发性和转移性肝癌的方法一直具有挑战性。原发性和继发性(转移性)肝癌的肝肿瘤微环境(TME)是异质的,由独特的免疫和基质细胞群组成。这些细胞群和肿瘤细胞之间的串扰在肝脏内创造了一个免疫抑制的微环境,从而加速了癌症的进展。免疫检查点抑制剂(ICIs)现已被临床批准用于原发性和继发性肝癌的治疗,并且可以部分克服肝脏免疫耐受,但其疗效有限。在这篇综述中,我们描述了肝脏微环境和免疫治疗在原发性和继发性肝癌中的应用。我们讨论了利用局部和全身治疗方法的新兴联合策略,这可能会提高原发性和继发性肝癌免疫治疗的疗效。对肝脏免疫抑制微环境的深入了解将为新的治疗方法和治疗组合提供信息,从而改善原发性和继发性肝癌患者的预后。
{"title":"Impact of immune tolerance mechanisms on the efficacy of immunotherapy in primary and secondary liver cancers.","authors":"Kamya Sankar,&nbsp;Ashley N Pearson,&nbsp;Tejaswi Worlikar,&nbsp;Matthew D Perricone,&nbsp;Erin A Holcomb,&nbsp;Mishal Mendiratta-Lala,&nbsp;Zhen Xu,&nbsp;Neil Bhowmick,&nbsp;Michael D Green","doi":"10.21037/tgh-23-11","DOIUrl":"https://doi.org/10.21037/tgh-23-11","url":null,"abstract":"<p><p>The liver is a functionally unique organ with an immunosuppressive microenvironment. The liver is the sixth most common site of primary cancer in humans and is a frequent site of metastasis from other solid tumors. The development of effective therapies for primary and metastatic liver cancer has been challenging due to the complex metabolic and immune microenvironment of the liver. The liver tumor microenvironment (TME) in primary and secondary (metastatic) liver cancers is heterogenous and consists of unique immune and stromal cell populations. Crosstalk between these cell populations and tumor cells creates an immunosuppressive microenvironment within the liver which potentiates cancer progression. Immune checkpoint inhibitors (ICIs) are now clinically approved for the management of primary and secondary liver cancer and can partially overcome liver immune tolerance, but their efficacy is limited. In this review, we describe the liver microenvironment and the use of immunotherapy in primary and secondary liver cancer. We discuss emerging combination strategies utilizing locoregional and systemic therapy approaches which may enhance efficacy of immunotherapy in primary and secondary liver cancer. A deeper understanding of the immunosuppressive microenvironment of the liver will inform novel therapies and therapeutic combinations in order to improve outcomes of patients with primary and secondary liver cancer.</p>","PeriodicalId":23267,"journal":{"name":"Translational gastroenterology and hepatology","volume":"8 ","pages":"29"},"PeriodicalIF":3.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5c/58/tgh-08-23-11.PMC10432235.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10305937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adenoma detection rate vs. adenoma per colonoscopy as quality indicators for colon cancer screening. 腺瘤检出率与单次结肠镜检查腺瘤作为结肠癌筛查的质量指标。
IF 3 4区 医学 Q1 Medicine Pub Date : 2023-01-01 DOI: 10.21037/tgh-22-92
Rizwan Ishtiaq, Laraib Zulfiqar, Manesh Kumar Gangwani, Muhammad Aziz
is known as the ‘One and done’ approach. In operators who are focused on using ADR as a quality indicator, it is very well possible that they may perform a quality examination until they find one adenoma and then unintentionally decrease the quality of the rest of the examination of the colonoscopy, which will indirectly affect the quality of the procedure without affecting ADR (7). Additionally, operator-based variability is also exhibited by differences in proximal and distal adenoma detection rate, and ADR metric by its calculable metric standard cannot account for these differences (8)
{"title":"Adenoma detection rate <i>vs</i>. adenoma per colonoscopy as quality indicators for colon cancer screening.","authors":"Rizwan Ishtiaq,&nbsp;Laraib Zulfiqar,&nbsp;Manesh Kumar Gangwani,&nbsp;Muhammad Aziz","doi":"10.21037/tgh-22-92","DOIUrl":"https://doi.org/10.21037/tgh-22-92","url":null,"abstract":"is known as the ‘One and done’ approach. In operators who are focused on using ADR as a quality indicator, it is very well possible that they may perform a quality examination until they find one adenoma and then unintentionally decrease the quality of the rest of the examination of the colonoscopy, which will indirectly affect the quality of the procedure without affecting ADR (7). Additionally, operator-based variability is also exhibited by differences in proximal and distal adenoma detection rate, and ADR metric by its calculable metric standard cannot account for these differences (8)","PeriodicalId":23267,"journal":{"name":"Translational gastroenterology and hepatology","volume":"8 ","pages":"24"},"PeriodicalIF":3.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2f/21/tgh-08-22-92.PMC10432231.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10406182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of severe acute pancreatitis in 2019. 2019年重症急性胰腺炎的管理。
IF 3 4区 医学 Q1 Medicine Pub Date : 2022-01-01 DOI: 10.21037/tgh-2020-08
Eddie Copelin, Jessica Widmer

Pancreatic fluid collections (PFCs) are frequent complications in severe acute pancreatitis that are the result of damage to the pancreas to include but not limited to trauma, surgery, autoimmune diseases, alcohol abuse, infections, medications, gallstones, metabolic disorders, and premalignant or malignant conditions. The majority of these collections resolve spontaneously; however, if the collection is infected or causes symptoms to include abdominal pain, nausea, vomiting, diarrhea, fevers, and tachycardia, drainage is indicated. Drainage of PFCs can be accomplished surgically, percutaneously, or endoscopically and should be approached in a multidisciplinary fashion for best overall patient care and outcomes. Before the introduction of endoscopic procedures, surgical and percutaneous drainage was the preferred modality. Today a minimally-invasive "step-up" approach is generally accepted depending upon the specific characteristics of the PFC and clinical presentation. Endoscopic ultrasound-guided PFC drainage is favored due to high success rates, shorter hospital stays, and lower cost. Direct debridement of walled-off pancreatitis can now be performed endoscopically with higher success rates with larger caliber fully covered metal stents. At large, the field of endoscopic techniques has evolved, and more specifically, the management of PFCs continues to evolve with increasing experience and with the advent of new stents and accessories, leading to increased efficacy with less adverse events.

胰液收集(pfc)是严重急性胰腺炎的常见并发症,是胰腺损伤的结果,包括但不限于创伤、手术、自身免疫性疾病、酗酒、感染、药物、胆结石、代谢紊乱、恶性或恶性前病变。这些集合中的大多数是自发解决的;但是,如果收集物受到感染或引起腹痛、恶心、呕吐、腹泻、发烧和心动过速等症状,则需要引流。pfc的引流可以通过手术、经皮或内窥镜完成,并应以多学科的方式进行,以获得最佳的整体患者护理和结果。在引入内窥镜手术之前,手术和经皮引流是首选的方式。目前,根据PFC的具体特征和临床表现,微创“升级”方法被普遍接受。超声内镜引导下的PFC引流因成功率高、住院时间短、费用低而受到青睐。采用大口径全覆盖金属支架,可在内窥镜下对壁闭塞性胰腺炎进行直接清创,成功率较高。总的来说,内窥镜技术领域已经发展,更具体地说,随着经验的增加和新支架和附件的出现,pfc的管理继续发展,从而提高了疗效,减少了不良事件。
{"title":"Management of severe acute pancreatitis in 2019.","authors":"Eddie Copelin,&nbsp;Jessica Widmer","doi":"10.21037/tgh-2020-08","DOIUrl":"https://doi.org/10.21037/tgh-2020-08","url":null,"abstract":"<p><p>Pancreatic fluid collections (PFCs) are frequent complications in severe acute pancreatitis that are the result of damage to the pancreas to include but not limited to trauma, surgery, autoimmune diseases, alcohol abuse, infections, medications, gallstones, metabolic disorders, and premalignant or malignant conditions. The majority of these collections resolve spontaneously; however, if the collection is infected or causes symptoms to include abdominal pain, nausea, vomiting, diarrhea, fevers, and tachycardia, drainage is indicated. Drainage of PFCs can be accomplished surgically, percutaneously, or endoscopically and should be approached in a multidisciplinary fashion for best overall patient care and outcomes. Before the introduction of endoscopic procedures, surgical and percutaneous drainage was the preferred modality. Today a minimally-invasive \"step-up\" approach is generally accepted depending upon the specific characteristics of the PFC and clinical presentation. Endoscopic ultrasound-guided PFC drainage is favored due to high success rates, shorter hospital stays, and lower cost. Direct debridement of walled-off pancreatitis can now be performed endoscopically with higher success rates with larger caliber fully covered metal stents. At large, the field of endoscopic techniques has evolved, and more specifically, the management of PFCs continues to evolve with increasing experience and with the advent of new stents and accessories, leading to increased efficacy with less adverse events.</p>","PeriodicalId":23267,"journal":{"name":"Translational gastroenterology and hepatology","volume":"7 ","pages":"16"},"PeriodicalIF":3.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9081916/pdf/tgh-07-2020-08.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10248972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Alagille syndrome and non-syndromic paucity of the intrahepatic bile ducts. 肝内胆管的Alagille综合征和非综合征性胆管缺乏。
IF 3 4区 医学 Q1 Medicine Pub Date : 2021-04-05 DOI: 10.21037/TGH-2019-RLD-12
Melissa A Gilbert, K. Loomes
The observation of bile duct paucity is an important diagnostic finding in children, occurring in roughly 11% of pediatric liver biopsies. Alagille syndrome (ALGS) is a well-defined syndromic form of intrahepatic bile duct paucity that is accompanied by a number of other key features, including cardiac, facial, ocular, and vertebral abnormalities. In the absence of these additional clinical characteristics, intrahepatic bile duct paucity results in a broad differential diagnosis that requires supplementary testing and characterization. Nearly 30 years after ALGS was first described, genetic studies identified a causative gene, JAGGED1, which spearheaded over two decades of research aimed to meticulously delineate the molecular underpinnings of ALGS. These advancements have characterized ALGS as a genetic disease and led to testing strategies that offer the ability to detect a pathogenic genetic variant in almost 97% of individuals with ALGS. Having a molecular understanding of ALGS has allowed for the development of numerous in vitro and in vivo disease models, which have provided hope and promise for the future generation of gene-based and protein-based therapies. Generation of these disease models has offered scientists a mechanism to study the dynamics of bile duct development and regeneration, and in doing so, produced tools that are applicable to the understanding of other congenital and acquired liver diseases.
胆管缺乏是一项重要的儿童诊断发现,约占11%的儿童肝活检。Alagille综合征(ALGS)是肝内胆管缺乏的一种明确的综合征形式,伴有许多其他关键特征,包括心脏、面部、眼部和椎体异常。在缺乏这些附加临床特征的情况下,肝内胆管缺乏导致广泛的鉴别诊断,需要补充检查和特征。在ALGS首次被描述近30年后,遗传学研究发现了一种致病基因JAGGED1,这是20多年来旨在细致描绘ALGS分子基础的研究的先驱。这些进步将ALGS定性为一种遗传性疾病,并导致检测策略能够在近97%的ALGS患者中检测到致病遗传变异。对ALGS的分子理解使得许多体外和体内疾病模型的发展成为可能,这为未来一代基于基因和基于蛋白质的治疗提供了希望和希望。这些疾病模型的产生为科学家们提供了一种研究胆管发育和再生动力学的机制,并在此过程中产生了适用于理解其他先天性和获得性肝脏疾病的工具。
{"title":"Alagille syndrome and non-syndromic paucity of the intrahepatic bile ducts.","authors":"Melissa A Gilbert, K. Loomes","doi":"10.21037/TGH-2019-RLD-12","DOIUrl":"https://doi.org/10.21037/TGH-2019-RLD-12","url":null,"abstract":"The observation of bile duct paucity is an important diagnostic finding in children, occurring in roughly 11% of pediatric liver biopsies. Alagille syndrome (ALGS) is a well-defined syndromic form of intrahepatic bile duct paucity that is accompanied by a number of other key features, including cardiac, facial, ocular, and vertebral abnormalities. In the absence of these additional clinical characteristics, intrahepatic bile duct paucity results in a broad differential diagnosis that requires supplementary testing and characterization. Nearly 30 years after ALGS was first described, genetic studies identified a causative gene, JAGGED1, which spearheaded over two decades of research aimed to meticulously delineate the molecular underpinnings of ALGS. These advancements have characterized ALGS as a genetic disease and led to testing strategies that offer the ability to detect a pathogenic genetic variant in almost 97% of individuals with ALGS. Having a molecular understanding of ALGS has allowed for the development of numerous in vitro and in vivo disease models, which have provided hope and promise for the future generation of gene-based and protein-based therapies. Generation of these disease models has offered scientists a mechanism to study the dynamics of bile duct development and regeneration, and in doing so, produced tools that are applicable to the understanding of other congenital and acquired liver diseases.","PeriodicalId":23267,"journal":{"name":"Translational gastroenterology and hepatology","volume":"19 1","pages":"22"},"PeriodicalIF":3.0,"publicationDate":"2021-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90804033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
Recent advances in Wilson disease. 威尔逊病的最新进展。
IF 3 4区 医学 Q1 Medicine Pub Date : 2021-04-05 DOI: 10.21037/TGH-2019-RLD-10
M. Moini, Uyen To, M. Schilsky
Wilson disease (WD) is rare genetic disorder that presents with varied phenotype that can at times make the diagnosis challenging. Medical treatments are available, but there are still unmet needs for patients. Since life-long therapy is necessary, adherence to medical therapy and best practices for monitoring and individualizing therapy continue to evolve. Studies are ongoing that address some of these issues. In the current review we focused our attention to recent advances in the diagnosis of WD, current medical treatments, future potential therapies and treatment monitoring. We include discussion of new methodology for detection and quantitation of ophthalmologic signs of WD, new brain imaging modalities for early detection of neurologic involvement in patients and potential new diagnostic methodology using blood samples that may be applicable to newborn screening and adult disease diagnosis. In addition, there are new strategies aimed at improving adherence and outcomes with currently available therapies, including once daily chelation dosing and discussion of the efficacy of different zinc salt compounds. With respect to new therapies with different mechanisms of action, we discuss studies on Bis-choline tetrathiomolybdate (TTM) in patients, pre-clinical studies of a novel chelator methanobactin and other animal studies exploring cures for WD with gene therapy using adeno-associated vectors (AAVs) that introduce ATP7B into liver cells. There are also promising advances in the more accurate measurement of non-ceruloplasmin bound copper and exchangeable copper in the circulation which would potentially help with monitoring and individualization of treatment and possibly play a role in future disease diagnosis.
威尔逊病(WD)是一种罕见的遗传疾病,表现为多种表型,有时使诊断具有挑战性。医学治疗是可行的,但患者的需求仍未得到满足。由于终身治疗是必要的,坚持药物治疗和监测和个性化治疗的最佳做法继续发展。针对其中一些问题的研究正在进行中。在当前的综述中,我们将重点关注WD诊断的最新进展,目前的医学治疗方法,未来潜在的治疗方法和治疗监测。我们讨论了检测和定量WD眼科征象的新方法,用于早期检测患者神经系统病变的新脑成像模式,以及可能适用于新生儿筛查和成人疾病诊断的使用血液样本的潜在新诊断方法。此外,还有一些新的策略旨在改善现有疗法的依从性和结果,包括每天一次螯合剂量和讨论不同锌盐化合物的疗效。关于具有不同作用机制的新疗法,我们讨论了双胆碱四硫钼酸盐(TTM)在患者中的研究,新型螯合剂methanobactin的临床前研究以及其他利用腺相关载体(aav)将ATP7B引入肝细胞的基因治疗WD的动物研究。在更精确地测量非铜蓝蛋白结合铜和循环中可交换铜方面也有希望取得进展,这可能有助于监测和个性化治疗,并可能在未来的疾病诊断中发挥作用。
{"title":"Recent advances in Wilson disease.","authors":"M. Moini, Uyen To, M. Schilsky","doi":"10.21037/TGH-2019-RLD-10","DOIUrl":"https://doi.org/10.21037/TGH-2019-RLD-10","url":null,"abstract":"Wilson disease (WD) is rare genetic disorder that presents with varied phenotype that can at times make the diagnosis challenging. Medical treatments are available, but there are still unmet needs for patients. Since life-long therapy is necessary, adherence to medical therapy and best practices for monitoring and individualizing therapy continue to evolve. Studies are ongoing that address some of these issues. In the current review we focused our attention to recent advances in the diagnosis of WD, current medical treatments, future potential therapies and treatment monitoring. We include discussion of new methodology for detection and quantitation of ophthalmologic signs of WD, new brain imaging modalities for early detection of neurologic involvement in patients and potential new diagnostic methodology using blood samples that may be applicable to newborn screening and adult disease diagnosis. In addition, there are new strategies aimed at improving adherence and outcomes with currently available therapies, including once daily chelation dosing and discussion of the efficacy of different zinc salt compounds. With respect to new therapies with different mechanisms of action, we discuss studies on Bis-choline tetrathiomolybdate (TTM) in patients, pre-clinical studies of a novel chelator methanobactin and other animal studies exploring cures for WD with gene therapy using adeno-associated vectors (AAVs) that introduce ATP7B into liver cells. There are also promising advances in the more accurate measurement of non-ceruloplasmin bound copper and exchangeable copper in the circulation which would potentially help with monitoring and individualization of treatment and possibly play a role in future disease diagnosis.","PeriodicalId":23267,"journal":{"name":"Translational gastroenterology and hepatology","volume":"36 1","pages":"21"},"PeriodicalIF":3.0,"publicationDate":"2021-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91286809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 21
The acute hepatic porphyrias. 急性肝卟啉症。
IF 3 4区 医学 Q1 Medicine Pub Date : 2021-04-05 DOI: 10.21037/TGH-2019-RLD-05
Bruce Wang
The acute hepatic porphyrias (AHP) are a group of four inherited diseases of heme biosynthesis. They present with similar severe, episodic, acute neurovisceral symptoms due to abnormally elevated levels of porphyrin precursors delta-aminolevulinic acid (ALA). Recently genetic screening indicates that the prevalence of mutation carrier state is more common than previously thought, occurring in 1 in 1,500, though the clinical penetrance of symptomatic AHP is low at ~1%. Symptomatic attacks occur primarily in females during their reproductive years. In an acute porphyria attack, the primary symptom is abdominal pain, due to intestinal dysmotility from autonomic nerve injury. Other manifestations include seizures, weakness and mood changes, point to injury involving peripheral and central nervous system. Due to the non-specific nature of the symptoms and signs in AHP, the diagnosis is often delayed by many years. The diagnosis of AHP depends on biochemical evidence of elevated ALA and PBG levels in urine during symptomatic attacks. Genetic testing is used for confirmation of the gene involved and the exact mutation. Treatment involves administration of heme, which downregulates production of ALA. Long-term management centers on educating genetic carriers on avoiding triggers that increase the risk of acute attacks and screening family members.
急性肝卟啉症(AHP)是一组四种遗传性血红素生物合成疾病。由于卟啉前体氨基乙酰丙酸(ALA)水平异常升高,他们表现出类似的严重、发作性、急性神经内脏症状。最近的基因筛查表明,突变携带者状态的患病率比以前认为的更普遍,发生率为1 / 1500,尽管有症状的AHP的临床外显率低至约1%。症状性发作主要发生在生育期的女性。在急性卟啉症发作时,主要症状是腹痛,这是由于自主神经损伤引起的肠道运动障碍。其他表现包括癫痫发作、虚弱和情绪变化,表明周围和中枢神经系统受到损伤。由于AHP的症状和体征的非特异性,诊断常常延迟许多年。AHP的诊断依赖于有症状发作时尿液中ALA和PBG水平升高的生化证据。基因检测用于确认所涉及的基因和确切的突变。治疗包括给予血红素,其下调ALA的产生。长期管理的重点是教育基因携带者避免增加急性发作风险的触发因素,并筛查家庭成员。
{"title":"The acute hepatic porphyrias.","authors":"Bruce Wang","doi":"10.21037/TGH-2019-RLD-05","DOIUrl":"https://doi.org/10.21037/TGH-2019-RLD-05","url":null,"abstract":"The acute hepatic porphyrias (AHP) are a group of four inherited diseases of heme biosynthesis. They present with similar severe, episodic, acute neurovisceral symptoms due to abnormally elevated levels of porphyrin precursors delta-aminolevulinic acid (ALA). Recently genetic screening indicates that the prevalence of mutation carrier state is more common than previously thought, occurring in 1 in 1,500, though the clinical penetrance of symptomatic AHP is low at ~1%. Symptomatic attacks occur primarily in females during their reproductive years. In an acute porphyria attack, the primary symptom is abdominal pain, due to intestinal dysmotility from autonomic nerve injury. Other manifestations include seizures, weakness and mood changes, point to injury involving peripheral and central nervous system. Due to the non-specific nature of the symptoms and signs in AHP, the diagnosis is often delayed by many years. The diagnosis of AHP depends on biochemical evidence of elevated ALA and PBG levels in urine during symptomatic attacks. Genetic testing is used for confirmation of the gene involved and the exact mutation. Treatment involves administration of heme, which downregulates production of ALA. Long-term management centers on educating genetic carriers on avoiding triggers that increase the risk of acute attacks and screening family members.","PeriodicalId":23267,"journal":{"name":"Translational gastroenterology and hepatology","volume":"5 1","pages":"24"},"PeriodicalIF":3.0,"publicationDate":"2021-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88298405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Rare and undiagnosed liver diseases: challenges and opportunities. 罕见和未确诊的肝病:挑战和机遇。
IF 3 4区 医学 Q1 Medicine Pub Date : 2021-04-05 DOI: 10.21037/TGH-2019-RLD-14
L. Fabris, M. Strazzabosco
According to the statement of the European Commission of Public Health, rare diseases (RDs) are a group of ‘life-threatening or chronically debilitating diseases which are of such low prevalence that special combined efforts are needed to address them’ (1). Epidemiological criteria are essential for their definition. In Europe, a disease whose prevalence is lower than one in 2,000 people is considered a RD, while in the USA prevalence of a RD is less than one in 1,500 people, derived from the definition of a disease affecting fewer than 200,000 Americans. The difference in the prevalence thresholds between Europe and the USA reflects the wide variability among individual jurisdictions dependent on the current estimates of the population size in the different countries (2). At present, about 7,000 different diseases are recognized as ‘rare’, and altogether, affect about 400 million people worldwide (3). In a considerable percentage of patients (nearly 30%), the diseases prolong into the adult age or manifest in the adult age. Thus, this is a field of medicine that concerns both pediatrician and adult physicians and spans across all medical and surgical specialties. Most RDs (about 80%) are caused by monogenic defects. However, a perturbed homeostatic response of the cell may activate other disease mechanisms, including autoimmunity and autoinflammation, susceptibility to infectious agents and cancer. In addition, the correlation between genotype and phenotype is often quite variable. In fact, in a number of RDs, affected genes control fundamental development processes resulting in a multifaceted clinical phenotype and multiorgan involvement. According to the Orphanet database, about 25% of rare patients die before 5 years, whereas an additional 37% have a reduced life expectancy, variably dependent on the severity of the RD (4). Too often, the diagnosis represents a big challenge. Because of the limited awareness of these conditions and the scarcity of centers with adequate clinical experience and laboratory skills, the diagnosis is difficult to achieve and is thus often delayed. Notably, the average time for a patient with a rare disease to receive an accurate diagnosis is nearly 5 years (3). Unfortunately, despite repeated costand time-consuming efforts, several (6%) remain undiagnosed (5). Even when a diagnosis is reached, often the treatment options are limited. In spite of the recent progresses, it is estimated that 95% of RDs still lack an FDA approved treatment. It may take 10–12 years for a new drug to be approved for the cure of rare disease patients (6). This long avenue is also partly dependent on the difficulties in conducting clinical trials in rare diseases (small cohorts of widely dispersed patients in both pediatric and adult age, lack of validated biomarkers and qualified endpoints). Therefore, RDs are also often referred to as ‘orphan’ to highlight the concept that effective treatments are lacking as not enough research and drug
根据欧洲公共卫生委员会的声明,罕见病(RDs)是一组“危及生命或慢性使人衰弱的疾病,其流行率极低,需要特别联合努力加以解决”(1)。流行病学标准对其定义至关重要。在欧洲,患病率低于1 / 2000的疾病被认为是RD,而在美国,RD的患病率低于1 / 1500,这是根据影响少于20万美国人的疾病的定义得出的。欧洲和美国之间患病率阈值的差异反映了不同司法管辖区之间的广泛差异,这取决于当前对不同国家人口规模的估计(2)。目前,约有7,000种不同的疾病被认为是“罕见的”,总共影响全球约4亿人(3)。在相当大比例的患者(近30%)中,这些疾病延续到成年期或在成年期表现出来。因此,这是一个涉及儿科医生和成人医生的医学领域,横跨所有医学和外科专业。大多数rd(约80%)是由单基因缺陷引起的。然而,受干扰的细胞内稳态反应可能激活其他疾病机制,包括自身免疫和自身炎症,对感染因子和癌症的易感性。此外,基因型和表型之间的相关性往往是可变的。事实上,在许多rd中,受影响的基因控制着基本的发育过程,导致多方面的临床表型和多器官参与。根据Orphanet数据库,大约25%的罕见患者在5岁前死亡,而另外37%的患者预期寿命缩短,这取决于RD的严重程度(4)。通常,诊断是一个很大的挑战。由于对这些疾病的认识有限,并且缺乏具有足够临床经验和实验室技能的中心,因此很难实现诊断,因此经常被延误。值得注意的是,患有罕见疾病的患者获得准确诊断的平均时间接近5年(3)。不幸的是,尽管反复不懈地付出了耗时的努力,仍有几个(6%)患者未被诊断出来(5)。即使确诊了,通常治疗方案也是有限的。尽管最近取得了进展,但据估计95%的rd仍然缺乏FDA批准的治疗方法。一种用于治疗罕见病患者的新药可能需要10-12年的时间才能获得批准(6)。这条漫长的道路也部分取决于在罕见病中进行临床试验的困难(儿童和成人中广泛分散的小队列患者,缺乏经过验证的生物标志物和合格的终点)。因此,rd也经常被称为“孤儿”,以强调缺乏有效治疗的概念,因为没有足够的研究和药物开发努力致力于这个问题。值得注意的是,只有二分之一的研发中心拥有基金会或研究支持小组,从而限制了获得资助的机会(3)。大多数研究资金被分配给最常见的疾病或作为对特定事件的反应。然而,应当指出的是,由于发现了新的细胞功能和目标,资助关于rd的研究也将有利于更普遍的疾病。
{"title":"Rare and undiagnosed liver diseases: challenges and opportunities.","authors":"L. Fabris, M. Strazzabosco","doi":"10.21037/TGH-2019-RLD-14","DOIUrl":"https://doi.org/10.21037/TGH-2019-RLD-14","url":null,"abstract":"According to the statement of the European Commission of Public Health, rare diseases (RDs) are a group of ‘life-threatening or chronically debilitating diseases which are of such low prevalence that special combined efforts are needed to address them’ (1). Epidemiological criteria are essential for their definition. In Europe, a disease whose prevalence is lower than one in 2,000 people is considered a RD, while in the USA prevalence of a RD is less than one in 1,500 people, derived from the definition of a disease affecting fewer than 200,000 Americans. The difference in the prevalence thresholds between Europe and the USA reflects the wide variability among individual jurisdictions dependent on the current estimates of the population size in the different countries (2). At present, about 7,000 different diseases are recognized as ‘rare’, and altogether, affect about 400 million people worldwide (3). In a considerable percentage of patients (nearly 30%), the diseases prolong into the adult age or manifest in the adult age. Thus, this is a field of medicine that concerns both pediatrician and adult physicians and spans across all medical and surgical specialties. Most RDs (about 80%) are caused by monogenic defects. However, a perturbed homeostatic response of the cell may activate other disease mechanisms, including autoimmunity and autoinflammation, susceptibility to infectious agents and cancer. In addition, the correlation between genotype and phenotype is often quite variable. In fact, in a number of RDs, affected genes control fundamental development processes resulting in a multifaceted clinical phenotype and multiorgan involvement. According to the Orphanet database, about 25% of rare patients die before 5 years, whereas an additional 37% have a reduced life expectancy, variably dependent on the severity of the RD (4). Too often, the diagnosis represents a big challenge. Because of the limited awareness of these conditions and the scarcity of centers with adequate clinical experience and laboratory skills, the diagnosis is difficult to achieve and is thus often delayed. Notably, the average time for a patient with a rare disease to receive an accurate diagnosis is nearly 5 years (3). Unfortunately, despite repeated costand time-consuming efforts, several (6%) remain undiagnosed (5). Even when a diagnosis is reached, often the treatment options are limited. In spite of the recent progresses, it is estimated that 95% of RDs still lack an FDA approved treatment. It may take 10–12 years for a new drug to be approved for the cure of rare disease patients (6). This long avenue is also partly dependent on the difficulties in conducting clinical trials in rare diseases (small cohorts of widely dispersed patients in both pediatric and adult age, lack of validated biomarkers and qualified endpoints). Therefore, RDs are also often referred to as ‘orphan’ to highlight the concept that effective treatments are lacking as not enough research and drug ","PeriodicalId":23267,"journal":{"name":"Translational gastroenterology and hepatology","volume":"1 1","pages":"18"},"PeriodicalIF":3.0,"publicationDate":"2021-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82289392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Evolution of the liver biopsy and its future. 肝活检的发展及其未来。
IF 3 4区 医学 Q1 Medicine Pub Date : 2021-01-01 DOI: 10.21037/tgh.2020.04.01
Dhanpat Jain, Richard Torres, Romulo Celli, Jeremy Koelmel, Georgia Charkoftaki, Vasilis Vasiliou
Liver biopsies are commonly used to evaluate a wide variety of medical disorders, including neoplasms and post-transplant complications. However, its use is being impacted by improved clinical diagnosis of disorders, and non-invasive methods for evaluating liver tissue and as a result the indications of a liver biopsy have undergone major changes in the last decade. The evolution of highly effective treatments for some of the common indications for liver biopsy in the last decade (e.g., viral hepatitis B and C) has led to a decline in the number of liver biopsies in recent years. At the same time, the emergence of better technologies for histologic evaluation, tissue content analysis and genomics are among the many new and exciting developments in the field that hold great promise for the future and are going to shape the indications for a liver biopsy in the future. Recent advances in slide scanners now allow creation of "digital/virtual" slides that have image of the entire tissue section present in a slide [whole slide imaging (WSI)]. WSI can now be done very rapidly and at very high resolution, allowing its use in routine clinical practice. In addition, a variety of technologies have been developed in recent years that use different light sources and/or microscopes allowing visualization of tissues in a completely different way. One such technique that is applicable to liver specimens combines multiphoton microscopy (MPM) with advanced clearing and fluorescent stains known as Clearing Histology with MultiPhoton Microscopy (CHiMP). Although it has not yet been extensively validated, the technique has the potential to decrease inefficiency, reduce artifacts, and increase data while being readily integrable into clinical workflows. Another technology that can provide rapid and in-depth characterization of thousands of molecules in a tissue sample, including liver tissues, is matrix assisted laser desorption/ionization (MALDI) mass spectrometry. MALDI has already been applied in a clinical research setting with promising diagnostic and prognostic capabilities, as well as being able to elucidate mechanisms of liver diseases that may be targeted for the development of new therapies. The logical next step in huge data sets obtained from such advanced analysis of liver tissues is the application of machine learning (ML) algorithms and application of artificial intelligence (AI), for automated generation of diagnoses and prognoses. This review discusses the evolving role of liver biopsies in clinical practice over the decades, and describes newer technologies that are likely to have a significant impact on how they will be used in the future.
肝活检通常用于评估各种各样的医学疾病,包括肿瘤和移植后并发症。然而,它的使用受到疾病临床诊断的改进和评估肝组织的非侵入性方法的影响,因此肝活检的适应症在过去十年中发生了重大变化。在过去十年中,对一些肝活检的常见适应症(例如病毒性乙型肝炎和丙型肝炎)的高效治疗方法的发展,导致近年来肝活检的数量下降。与此同时,组织学评估、组织含量分析和基因组学等更好的技术的出现,是该领域许多令人兴奋的新发展之一,它们对未来有着巨大的希望,并将在未来形成肝活检的适应症。切片扫描仪的最新进展现在允许创建“数字/虚拟”切片,在切片上显示整个组织切片的图像[全切片成像(WSI)]。WSI现在可以非常快速和非常高的分辨率完成,允许它在常规临床实践中使用。此外,近年来已经开发了各种技术,使用不同的光源和/或显微镜,可以以完全不同的方式可视化组织。一种适用于肝脏标本的技术将多光子显微镜(MPM)与先进的清除和荧光染色相结合,称为多光子显微镜清除组织学(CHiMP)。虽然尚未得到广泛验证,但该技术具有降低效率、减少人工制品和增加数据的潜力,同时易于集成到临床工作流程中。另一种可以快速深入表征组织样本(包括肝组织)中数千个分子的技术是基质辅助激光解吸/电离(MALDI)质谱法。MALDI已经应用于临床研究环境,具有很好的诊断和预后能力,并且能够阐明肝脏疾病的机制,可能成为开发新疗法的目标。从如此先进的肝组织分析中获得的庞大数据集的下一步逻辑是应用机器学习(ML)算法和应用人工智能(AI),以自动生成诊断和预后。这篇综述讨论了几十年来肝活检在临床实践中不断发展的作用,并描述了可能对肝活检在未来的应用产生重大影响的新技术。
{"title":"Evolution of the liver biopsy and its future.","authors":"Dhanpat Jain,&nbsp;Richard Torres,&nbsp;Romulo Celli,&nbsp;Jeremy Koelmel,&nbsp;Georgia Charkoftaki,&nbsp;Vasilis Vasiliou","doi":"10.21037/tgh.2020.04.01","DOIUrl":"https://doi.org/10.21037/tgh.2020.04.01","url":null,"abstract":"Liver biopsies are commonly used to evaluate a wide variety of medical disorders, including neoplasms and post-transplant complications. However, its use is being impacted by improved clinical diagnosis of disorders, and non-invasive methods for evaluating liver tissue and as a result the indications of a liver biopsy have undergone major changes in the last decade. The evolution of highly effective treatments for some of the common indications for liver biopsy in the last decade (e.g., viral hepatitis B and C) has led to a decline in the number of liver biopsies in recent years. At the same time, the emergence of better technologies for histologic evaluation, tissue content analysis and genomics are among the many new and exciting developments in the field that hold great promise for the future and are going to shape the indications for a liver biopsy in the future. Recent advances in slide scanners now allow creation of \"digital/virtual\" slides that have image of the entire tissue section present in a slide [whole slide imaging (WSI)]. WSI can now be done very rapidly and at very high resolution, allowing its use in routine clinical practice. In addition, a variety of technologies have been developed in recent years that use different light sources and/or microscopes allowing visualization of tissues in a completely different way. One such technique that is applicable to liver specimens combines multiphoton microscopy (MPM) with advanced clearing and fluorescent stains known as Clearing Histology with MultiPhoton Microscopy (CHiMP). Although it has not yet been extensively validated, the technique has the potential to decrease inefficiency, reduce artifacts, and increase data while being readily integrable into clinical workflows. Another technology that can provide rapid and in-depth characterization of thousands of molecules in a tissue sample, including liver tissues, is matrix assisted laser desorption/ionization (MALDI) mass spectrometry. MALDI has already been applied in a clinical research setting with promising diagnostic and prognostic capabilities, as well as being able to elucidate mechanisms of liver diseases that may be targeted for the development of new therapies. The logical next step in huge data sets obtained from such advanced analysis of liver tissues is the application of machine learning (ML) algorithms and application of artificial intelligence (AI), for automated generation of diagnoses and prognoses. This review discusses the evolving role of liver biopsies in clinical practice over the decades, and describes newer technologies that are likely to have a significant impact on how they will be used in the future.","PeriodicalId":23267,"journal":{"name":"Translational gastroenterology and hepatology","volume":"6 ","pages":"20"},"PeriodicalIF":3.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7829074/pdf/tgh-06-2020.04.01.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10176298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 15
Novel approaches to liver disease diagnosis and modeling. 肝脏疾病诊断和建模的新方法。
IF 3 4区 医学 Q1 Medicine Pub Date : 2021-01-01 DOI: 10.21037/tgh-20-109
André G Oliveira, Romina Fiorotto

Lack of a prompt and accurate diagnosis remains on top of the list of challenges faced by patients with rare liver diseases. Although rare liver diseases affect a significant percentage of the population as a group, when taken singularly they represent unique diseases and the approaches used for diagnosis of common liver diseases are insufficient. However, the development of new methods for the acquisition of molecular and clinical data (i.e., genomic, proteomics, metabolomics) and computational tools for their analysis and integration, together with advances in modeling diseases using stem cell-based technology [i.e., induced pluripotent stem cells (iPSCs) and tissue organoids] represent a promising and powerful tool to improve the clinical management of these patients. This is the goal of precision medicine, a novel approach of modern medicine that aims at delivering a specific treatment based on disease-specific biological insights and individual profile. This review will discuss the application and advances of these technologies and how they represent a new opportunity in hepatology.

缺乏及时和准确的诊断仍然是罕见肝病患者面临的首要挑战。虽然罕见的肝脏疾病作为一个群体影响人口的很大比例,但单独来看,它们是独特的疾病,用于诊断常见肝脏疾病的方法是不够的。然而,获取分子和临床数据(即基因组学、蛋白质组学、代谢组学)的新方法的发展和用于分析和整合这些数据的计算工具的发展,以及利用基于干细胞的技术(即诱导多能干细胞(iPSCs)和组织类器官)对疾病建模的进展,代表了改善这些患者临床管理的一个有希望和强大的工具。这就是精准医学的目标。精准医学是现代医学的一种新方法,旨在根据疾病特异性的生物学见解和个体特征提供特定的治疗。本文将讨论这些技术的应用和进展,以及它们如何代表了肝病学的新机遇。
{"title":"Novel approaches to liver disease diagnosis and modeling.","authors":"André G Oliveira,&nbsp;Romina Fiorotto","doi":"10.21037/tgh-20-109","DOIUrl":"https://doi.org/10.21037/tgh-20-109","url":null,"abstract":"<p><p>Lack of a prompt and accurate diagnosis remains on top of the list of challenges faced by patients with rare liver diseases. Although rare liver diseases affect a significant percentage of the population as a group, when taken singularly they represent unique diseases and the approaches used for diagnosis of common liver diseases are insufficient. However, the development of new methods for the acquisition of molecular and clinical data (i.e., genomic, proteomics, metabolomics) and computational tools for their analysis and integration, together with advances in modeling diseases using stem cell-based technology [i.e., induced pluripotent stem cells (iPSCs) and tissue organoids] represent a promising and powerful tool to improve the clinical management of these patients. This is the goal of precision medicine, a novel approach of modern medicine that aims at delivering a specific treatment based on disease-specific biological insights and individual profile. This review will discuss the application and advances of these technologies and how they represent a new opportunity in hepatology.</p>","PeriodicalId":23267,"journal":{"name":"Translational gastroenterology and hepatology","volume":"6 ","pages":"19"},"PeriodicalIF":3.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7829068/pdf/tgh-06-20-109.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9185308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
Bariatric surgery, obesity and liver transplantation. 减肥手术,肥胖和肝移植。
IF 3 4区 医学 Q1 Medicine Pub Date : 2021-01-01 DOI: 10.21037/TGH-2019-LTNA-15
Zunirah Ahmed, M. A. Khan, L. M. Vazquez-Montesino, Aijaz Ahmed
The obesity epidemic has profoundly impacted the epidemiology and trends of liver disease. In the current era, non-alcoholic fatty liver disease (NAFLD) progressing to non-alcoholic steatohepatitis (NASH) has emerged as the second leading indication for liver transplant (LT) and has been associated with the rising rates of hepatocellular carcinoma (HCC) with and without underlying cirrhosis. Obesity has been associated with poor post-transplant outcomes including lower patient and graft survival; higher risk of post-operative metabolic complications; poor wound healing; and higher infection rates. Bariatric surgery is currently the most effective management of morbid obesity and has been offered to patients both in the pre and post LT setting. The techniques attempted in LT recipients most commonly include sleeve gastrectomy (SG), gastric bypass surgery with few cases of gastric banding and biliopancreatic diversion. However, there is lack of evidence-based data on the optimal management for patients with obesity and who are liver transplant candidates and/or recipients. In the following discussion, we present the highlights from a review of the literature.
肥胖的流行已经深刻地影响了肝病的流行病学和趋势。在当今时代,非酒精性脂肪性肝病(NAFLD)进展为非酒精性脂肪性肝炎(NASH)已成为肝移植(LT)的第二大适应症,并与伴或不伴肝硬化的肝细胞癌(HCC)发病率上升相关。肥胖与移植后不良预后相关,包括患者和移植物存活率较低;术后代谢并发症风险较高;伤口愈合不良;以及更高的感染率。减肥手术是目前治疗病态肥胖最有效的方法,在肝移植术前和术后均有应用。肝移植受者最常尝试的技术包括袖胃切除术(SG)、胃旁路手术(少数病例为胃束带和胆道转移)。然而,对于肥胖患者和肝移植候选人和/或接受者的最佳管理,缺乏循证数据。在接下来的讨论中,我们从文献综述中提出重点。
{"title":"Bariatric surgery, obesity and liver transplantation.","authors":"Zunirah Ahmed, M. A. Khan, L. M. Vazquez-Montesino, Aijaz Ahmed","doi":"10.21037/TGH-2019-LTNA-15","DOIUrl":"https://doi.org/10.21037/TGH-2019-LTNA-15","url":null,"abstract":"The obesity epidemic has profoundly impacted the epidemiology and trends of liver disease. In the current era, non-alcoholic fatty liver disease (NAFLD) progressing to non-alcoholic steatohepatitis (NASH) has emerged as the second leading indication for liver transplant (LT) and has been associated with the rising rates of hepatocellular carcinoma (HCC) with and without underlying cirrhosis. Obesity has been associated with poor post-transplant outcomes including lower patient and graft survival; higher risk of post-operative metabolic complications; poor wound healing; and higher infection rates. Bariatric surgery is currently the most effective management of morbid obesity and has been offered to patients both in the pre and post LT setting. The techniques attempted in LT recipients most commonly include sleeve gastrectomy (SG), gastric bypass surgery with few cases of gastric banding and biliopancreatic diversion. However, there is lack of evidence-based data on the optimal management for patients with obesity and who are liver transplant candidates and/or recipients. In the following discussion, we present the highlights from a review of the literature.","PeriodicalId":23267,"journal":{"name":"Translational gastroenterology and hepatology","volume":"19 1","pages":"25"},"PeriodicalIF":3.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88498566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
期刊
Translational gastroenterology and hepatology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1